瘤坏死因子抑制剂治疗增加了绝对淋巴细胞计数,并与患有牛皮病关节炎的患者的较低死亡率有关

Lenche Kostadinova1,2, Brigid Wilson1,2, Hinnah Siddiqui1

  • 1Northeast Ohio Veterans Affairs Medical Center, Cleveland.

ACR open rheumatology
|December 16, 2025
PubMed
概括

瘤坏死因子抑制剂 (TNFi) 治疗增加了牛皮关节炎 (PsA) 患者的绝对淋巴细胞计数 (ALC),从而改善了生存率. 这一发现表明TNFi影响T细胞平衡,并可能降低PsA的死亡率.

相关概念视频

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445